An experimental messenger RNA (mRNA) cancer vaccine has generated positive data in combination with Keytruda (pembrolizumab) in patients with advanced melanoma, the developers Moderna Inc and Merck & Co announced on 13 December. ---Subscribe to MedNous to access this article--- Clinical Research Company News
